Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) EBITDA (2023 - 2025)

Kura Oncology (KURA) has disclosed EBITDA for 3 consecutive years, with -$80.9 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 313.37% to -$80.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$278.4 million through Dec 2025, down 61.91% year-over-year, with the annual reading at -$278.4 million for FY2025, 61.91% down from the prior year.
  • EBITDA for Q4 2025 was -$80.9 million at Kura Oncology, down from -$73.9 million in the prior quarter.
  • The five-year high for EBITDA was -$19.6 million in Q4 2024, with the low at -$80.9 million in Q4 2025.
  • Average EBITDA over 3 years is -$49.7 million, with a median of -$49.8 million recorded in 2024.
  • The sharpest move saw EBITDA skyrocketed 51.71% in 2024, then crashed 313.37% in 2025.
  • Over 3 years, EBITDA stood at -$40.5 million in 2023, then surged by 51.71% to -$19.6 million in 2024, then plummeted by 313.37% to -$80.9 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$80.9 million, -$73.9 million, and -$66.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.